Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;34(9):489-96.
doi: 10.1016/j.tips.2013.07.005. Epub 2013 Aug 20.

Mechanisms of dopamine transporter regulation in normal and disease states

Roxanne A Vaughan  1 , James D Foster
Affiliations
Review

Mechanisms of dopamine transporter regulation in normal and disease states

Roxanne A Vaughan et al. Trends Pharmacol Sci. 2013 Sep.

Abstract

The dopamine (DA) transporter (DAT) controls the spatial and temporal dynamics of DA neurotransmission by driving reuptake of extracellular transmitter into presynaptic neurons. Many diseases such as depression, bipolar disorder, Parkinson's disease (PD), and attention deficit hyperactivity disorder (ADHD) are associated with abnormal DA levels, implicating DAT as a factor in their etiology. Medications used to treat these disorders and many addictive drugs target DAT and enhance dopaminergic signaling by suppressing transmitter reuptake. We now understand that the transport and binding properties of DAT are regulated by complex and overlapping mechanisms that provide neurons with the ability to modulate DA clearance in response to physiological demands. These processes are controlled by endogenous signaling pathways and affected by exogenous transporter ligands, demonstrating their importance for normal neurotransmission, drug abuse, and disease treatments. Increasing evidence supports the disruption of these mechanisms in DA disorders, implicating dysregulation of transport in disease etiologies and suggesting these processes as potential points for therapeutic manipulation of DA availability.

Keywords: Parkinson's disease; amphetamine; attention deficit hyperactivity disorder; bipolar disorder; cocaine; drug addiction.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Regulatory elements of rat dopamine transporter N- and C-terminal domains
A 3D model of rat DAT based on the A. aeolicus LeuT transporter was generated using PyMol (Schrödinger, LLC), with TM helices shown as barrels and light shading indicating semitransparent Connolly surfaces. The structure was positioned in a membrane bilayer with schematic depictions of N- and C-terminal tails extending into the cytoplasm. Posttranslational modifications shown are Ser7, Ser13, and Thr53 phosphorylation (blue, P), Lys19 and Lys35 ubiquitylation (light green, Ub), and Cys580 palmitoylation (red, Pal). Motifs and sequences indicated are intracellular gate residue Arg60 (R, purple), putative Src homology domain epitope (mauve, SH3), PKC endocytosis motif (blue, FREK), and domains for interactions with Syntaxin 1A (Syn1A, yellow), D2 DA receptor (D2R, green) Ras-like GTPase Rin 1 (Rin, blue), Calcium-Calmodulin-Dependent Protein Kinase (CaMK, green), and α-synuclein (α-Syn, orange) and Parkin (Park, dark blue-lavender). Flotillin 1 (Flot 1, olive green) is shown with palmitic acid modification (red line) but without a known DAT interaction site.
Figure 2
Figure 2. Selected coding variants and potential CRAC motifs in DAT
(a) Coding variants known to alter DAT function (numbered yellow circles) and helical topological 2D architecture of DAT depicting essential cholesterol interacting residues in putative CRAC motifs (black circles with white letters). (b) Sequence alignment of human DAT, NET, and SERT showing homology within putative CRAC motifs. Residues that are key components of the motifs are shown in red; the numbers above the sequence correspond to hDAT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Manepalli S, et al. Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective. The AAPS journal. 2012;14:820–831. - PMC - PubMed
    1. Pramod AB, et al. SLC6 transporters: Structure, function, regulation, disease association and therapeutics. Mol Aspects Med. 2013;34:197–219. - PMC - PubMed
    1. Shan J, et al. The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. PLoS One. 2011;6:e16350. - PMC - PubMed
    1. Beuming T, et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci. 2008;11:780–789. - PMC - PubMed
    1. Ingram SL, et al. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat Neurosci. 2002;5:971–978. - PubMed

Publication types

MeSH terms

Substances